Physician profile
Kenneth H Chen
NPI 1902883010
$3,615.43
in general payments reported to CMS, 2019-2025
30 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $243 · 2021: $431 · 2022: $404 · 2023: $687 · 2024: $799 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.79 | 2019-2024 | Lo Loestrin Fe, Liletta, Orilissa |
| Amgen INC. | $359.06 | 2019-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $303.77 | 2021-2025 | |
| Pfizer INC. | $231.00 | 2022-2024 | |
| Therapeuticsmd, INC. | $216.59 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $215.42 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $195.00 | 2023-2025 | Accrufer |
| Evofem Biosciences, INC. | $161.23 | 2021-2024 | Phexxi |
| Exeltis, USA INC. | $139.32 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $135.27 | 2024-2025 | Veozah, Myrbetriq |
| Lupin INC. | $122.97 | 2019 | |
| Hologic Sales and Service, LLC | $109.51 | 2021-2024 | Aptima |
| Mylan Pharmaceuticals INC. | $72.72 | 2020-2021 | |
| Agile Therapeutics, INC. | $58.48 | 2021-2024 | Twirla |
| Amag Pharmaceuticals, INC. | $55.32 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $43.19 | 2021-2022 | |
| Si-Bone, INC. | $39.45 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.16 | 2019-2025 | |
| Coopersurgical, INC. | $32.09 | 2024-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $31.96 | 2024 | Gardasil 9, Gardasil |
| Scynexis, INC. | $27.74 | 2022 | |
| Coloplast Corp | $26.31 | 2019 | |
| Avion Pharmaceuticals | $25.68 | 2019-2021 | |
| Allergan, INC. | $25.42 | 2019-2020 | |
| Medicem INC. | $25.23 | 2021 | |
| Millicent US INC | $24.84 | 2019-2020 | |
| Convatec INC. | $24.66 | 2023 | |
| Vertical Pharmaceuticals, LLC | $24.21 | 2019 | |
| Sage Therapeutics, LLC | $19.91 | 2024 | |
| Dysis Medical, INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.